Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

JediGreen Mar. 17 at 1:20 AM

$BCTX Poster titles and presentation details will become available on March 17, 2026 at 4:30 PM ET, when the abstracts will be published in the online Proceedings of AACR. Should be interesting to see what the titles are.

0 · Reply

2maligators Mar. 17 at 1:00 AM

$BCTX we’re always so surprised when this goes up and wondering what’s going on?! It’s normal for it to go down and so easy to drop after our short gains. Can’t wait until tides turn and it’s the opposite. Believe it or not there was a time when this constantly went up and up fast..not many were around for it probably the ones that our stuck like me know about it. It’s been many years but I’ve experienced it and it’s something. I can only have hope n dreams at this point! Gluck everyone #believe#sellat50atleast

0 · Reply

dlev18 Mar. 16 at 9:10 PM

$BCRX check out $BCTX for the vibes

0 · Reply

dlev18 Mar. 16 at 12:32 PM

$BCTX wish I could buy more

1 · Reply

JediGreen Mar. 16 at 5:52 AM

$BCTX Got to hurry up and get rich. Sitting in 2 feet of snow right now and it’s just getting started. Hawaii I’m trying hard to make it to you. ⛄️ 🌴

1 · Reply

Mateuszrozek Mar. 13 at 1:48 PM

$BCTX when are we hitting 13?

2 · Reply

durocali Mar. 12 at 6:31 PM

$BCTX april 2030 warrants (BCTXZ): exercise price $5.25 -- trading today at $0.14; jan 2031 warrants (BCTXL): exercise price $6.93 -- trading today at $1.07.

1 · Reply

EscapePlan Mar. 12 at 4:03 PM

$BCTX This is fast becoming my "all or nothing" gamble for the year. I'm up to 30,000 warrants now. Really hoping for a solid trial update in Q2 that jumps this up to the 20s and gives me $400,000+!

1 · Reply

JJBurch Mar. 12 at 3:20 PM

$BCTX added more today

0 · Reply

rp6577 Mar. 12 at 11:45 AM

$BCTX the next few months could get very interesting

0 · Reply

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 11 days ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 26 days ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

Wed, 18 Feb 2026 17:30:00 -0500 - 26 days ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Tue, 17 Feb 2026 07:30:00 -0500 - 27 days ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 6 weeks ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

Wed, 28 Jan 2026 07:30:00 -0500 - 6 weeks ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 6 weeks ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

Tue, 27 Jan 2026 07:30:00 -0500 - 6 weeks ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 2 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 2 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 2 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 2 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 2 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 2 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 2 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

2026-01-14T06:35:20.000Z - 2 months ago

BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit

2026-01-14T06:35:20.000Z - 2 months ago

BriaCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit

Tue, 13 Jan 2026 21:00:00 -0500 - 2 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 2 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:08:02.000Z - 2 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 2 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Tue, 13 Jan 2026 07:30:00 -0500 - 2 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 3 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T13:29:00.000Z - 3 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

Wed, 10 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T13:34:16.000Z - 3 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

Tue, 09 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:50:27.000Z - 3 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

Tue, 02 Dec 2025 07:30:00 -0500 - 3 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

2025-12-01T12:53:14.000Z - 3 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

Tue, 25 Nov 2025 07:30:00 -0500 - 3 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T13:28:07.000Z - 4 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

Thu, 20 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Tue, 18 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tue, 04 Nov 2025 07:30:00 -0500 - 4 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-28T08:01:00.000Z - 4 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-27T19:05:00.000Z - 5 months ago

Top 3 Earnings Acceleration Buys for November

2025-10-22T12:51:17.000Z - 5 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

Wed, 22 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2025-10-21T20:52:14.000Z - 5 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T13:25:38.000Z - 5 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T12:50:54.000Z - 5 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

Tue, 21 Oct 2025 07:50:00 -0400 - 5 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Tue, 21 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

2025-10-20T13:31:42.000Z - 5 months ago

BriaCell (BCTX) Reports Promising Biomarker Data in Phase 3 Breast Cancer Study

Mon, 20 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

2025-10-13T13:27:39.000Z - 5 months ago

BriaCell (BCTX) to Present Key Phase 3 Study Data at ESMO Congress 2025

Mon, 13 Oct 2025 07:30:00 -0400 - 5 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 5 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 7 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 7 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 7 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 8 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 8 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 8 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 8 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 8 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 9 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 10 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 10 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 10 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 11 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 11 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 11 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

JediGreen Mar. 17 at 1:20 AM

0 · Reply

2maligators Mar. 17 at 1:00 AM

0 · Reply

dlev18 Mar. 16 at 9:10 PM

$BCRX check out $BCTX for the vibes

0 · Reply

dlev18 Mar. 16 at 12:32 PM

$BCTX wish I could buy more

1 · Reply

JediGreen Mar. 16 at 5:52 AM

$BCTX Got to hurry up and get rich. Sitting in 2 feet of snow right now and it’s just getting started. Hawaii I’m trying hard to make it to you. ⛄️ 🌴

1 · Reply

Mateuszrozek Mar. 13 at 1:48 PM

$BCTX when are we hitting 13?

2 · Reply

durocali Mar. 12 at 6:31 PM

$BCTX april 2030 warrants (BCTXZ): exercise price $5.25 -- trading today at $0.14; jan 2031 warrants (BCTXL): exercise price $6.93 -- trading today at $1.07.

1 · Reply

EscapePlan Mar. 12 at 4:03 PM

$BCTX This is fast becoming my "all or nothing" gamble for the year. I'm up to 30,000 warrants now. Really hoping for a solid trial update in Q2 that jumps this up to the 20s and gives me $400,000+!

1 · Reply

JJBurch Mar. 12 at 3:20 PM

$BCTX added more today

0 · Reply

rp6577 Mar. 12 at 11:45 AM

$BCTX the next few months could get very interesting

0 · Reply

JediGreen Mar. 11 at 11:59 PM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html

0 · Reply

TILResearch Mar. 11 at 8:29 PM

$BCTX anybody else think the $BCTXL warrants feel cheap currently? I'm thinking that's a pretty good way to buy into this company. These warrants give a person the right to buy 1 share of BCTX for $6.93 on or before January 2031. They are currently trading for ~$1 so break even is ~$8 which seems totally feasible if they have good interim readout.

2 · Reply

BadensBester Mar. 11 at 8:03 PM

$BCTX

0 · Reply

EscapePlan Mar. 11 at 7:46 PM

$BCTX 10Q came out last night. $30M in cash in Jan. $7.5M cash burn per quarter means that they now have a cash runway to last until 2027 Jan. Still targeting H1 readout. Current market cap is $30M (so same as cash position). They've spent around $200M getting to this point, so even if the share price just rises enough to represent everything the company has spent developing their products, you're looking at a SP of $28. So, for me, my target with positive news on H1 readout would be $28. Welcome thoughts from brighter folks on this board.....

1 · Reply

Princeb Mar. 11 at 7:40 PM

$BCTX volume 30x normal

1 · Reply

Dadisong Mar. 11 at 6:47 PM

$BCTX Hola, sinceramente es una VERGÜENZA como tiene el CEO la cotización de este Stock. No esperéis nada bueno de este CEO su trayectoria lo delata, es uno más de los muchos Presidentes INHUMANO.

2 · Reply

Orlandotrader Mar. 11 at 6:36 PM

$BCTX BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA. Generating some Excitement Today.

0 · Reply

TWBXX Mar. 11 at 6:29 PM

$BCTX Must be some positive news coming that retail never knows about in advance.

1 · Reply

NeverBearTrader2025 Mar. 11 at 6:07 PM

$BCTX Please can someone shed light on why this is up so much and still not losing the gains? I was not able to find the news.

3 · Reply

Hannibal_Smith Mar. 11 at 5:04 PM

$BCTX For H1 FY2026, net loss attributable to shareholders was USD 15.42 million, and total operating expenses increased 29% to USD 15.85 million. BriaCell ended Q2 with positive working capital of USD 28.99 million, and said its Bria-IMT Phase 3 metastatic breast cancer study had screened over 230 patients and enrolled over 160, with topline data on track for 1H2026.

0 · Reply

Kirubin Mar. 11 at 4:37 PM

$BCTX I will join you guys at $5.50! So far the market is saying it has reached bottom at this level!

1 · Reply

DwigtMcDichael Mar. 11 at 4:33 PM

$BCTX https://open.substack.com/pub/biotechdistilled/p/update-briacell-bctx-a-safety-nod?r=2pxc9l&utm_medium=ios

1 · Reply

Market Cap	30.60M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	128,900
Avg Vol	559,722
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	88%
Beta	1.46
Analysts	Strong Buy
Price Target	$40.00